Drug-eluting bead (DEB)

Cationic chemotherapeutic small molecules at a bead surface refers to a specialized drug delivery platform known as drug-eluting beads (DEBs), primarily used in transarterial chemoembolization (TACE) for liver malignancies. These beads are typically composed of biocompatible hydrogels, such as polyvinyl alcohol (PVA), which are modified with anionic sulfonate groups to facilitate the loading of cationic (positively charged) drugs like doxorubicin or irinotecan via ion exchange (Lewis et al., 2006). When administered into the hepatic artery, the beads physically block the blood supply to the tumor, inducing ischemia, while simultaneously providing a sustained and localized release of the chemotherapy agent directly into the neoplastic tissue (NIH, 2023). This dual mechanism aims to maximize the therapeutic index by achieving high intratumoral drug concentrations while significantly reducing systemic exposure and associated side effects (Varela et al., 2007). Because this term describes a delivery vehicle and its payload rather than a biological receptor, enzyme, or protein, it is classified as a drug-device combination rather than a therapeutic target.

Other names

Drug-eluting microsphereDEB-TACEIon-exchange beadCationic drug-loaded microsphereDC BeadHepaSphere

The system functions through ion-exchange mediated drug loading and controlled release; negatively charged (anionic) functional groups on the bead surface bind positively charged (cationic) chemotherapy molecules, which are then released in exchange for endogenous cations upon delivery into the tumor vasculature, combined with mechanical embolization to induce ischemia (Lewis et al., 2006; Varela et al., 2007).